(S)-1-methyl-3-(((1-phenylethyl)amino)methyl)quinoxalin-2(1H)-one | 791068-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (S)-1-methyl-3-(((1-phenylethyl)amino)methyl)quinoxalin-2(1H)-one
• 英文别名: (S)-1-methyl-3-[(1-phenyl-ethylamino)methyl]-1H-quinoxalin-2-one；1-methyl-3-[[[(1S)-1-phenylethyl]amino]methyl]quinoxalin-2-one
• CAS: 791068-36-5
• 化学式: C₁₈H₁₉N₃O
• 分子量: 293.368
• InChiKey: ZALYMLZRQSBIGJ-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(diethoxymethyl)-1-methylquinoxalin-2(1H)-one 在 盐酸 、 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 21.0h， 生成 (S)-1-methyl-3-(((1-phenylethyl)amino)methyl)quinoxalin-2(1H)-one
  参考文献：
  名称：

  Photocatalytic Transition‐Metal‐Free Direct 3‐Acetalation of Quinoxaline‐2( 1 H )‐ones

  摘要：

  Comprehensive SummaryA general transition‐metal‐free visible‐light‐promoted 3‐acetalation reaction of quinoxaline‐2(1H)‐ones was developed under mild conditions. By employing 1,2,3,5‐tetrakis(carbazol‐9‐yl)‐4,6‐dicyanobenzene (4CzIPN) as an inexpensive photocatalyst, and glyoxylic acid acetal as a radical source, various acetalated quinoxaline‐2(1H)‐ones were constructed in moderate to good yields. Moreover, the versatility of this protocol is highlighted by the successful application in the late‐stage modification of drug molecules and the various functionality transformations. The excellent antitumor activity of the acetalated product demonstrated that this streamlined and sustainable approach could have emerged as a powerful strategy for structural modification in medicinal chemistry.

  DOI：

  10.1002/cjoc.202200386

文献信息

• [EN] QUINOXALINONE-3- ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE QUINOXALINONE-3- ONE UTILISES COMME ANTAGONISTES DU RECEPTEUR D'OREXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004096780A1

  公开（公告）日：2004-11-11

  The invention relates to quinoxalinone derivatives of general Formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.General Formula (I) wherein X and R1-R9 are as defined in the description

  本发明涉及一般式(I)的喹喔啉酮衍生物及其在制备药物组合物中作为活性成分的用途。本发明还涉及相关方面，包括制备该化合物的过程，含有一个或多个该化合物的药物组合物，特别是它们作为促进睡眠的药物受体拮抗剂的用途。其中X和R1-R9如描述中所定义。
• Quinoxalinone-3-one derivatives as orexin receptor antagonists
  申请人：Aissaoui Hamed

  公开号：US20070027157A1

  公开（公告）日：2007-02-01

  The invention relates to quinoxalinone derivatives of general Formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists. General Formula (I) wherein X and R 1 -R 9 are as defined in the description

  该发明涉及通式（I）的喹喔啉酮衍生物及其作为制备药物组分的活性成分的使用。该发明还涉及相关方面，包括制备该化合物的过程，含有其中一种或多种化合物的药物组合物，特别是它们作为促进睡眠荷尔蒙受体拮抗剂的用途。通式（I）中X和R1-R9如说明中所定义。
• QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1620409A1

  公开（公告）日：2006-02-01
• US7538109B2
  申请人：——

  公开号：US7538109B2

  公开（公告）日：2009-05-26
• Photocatalytic <scp>Transition‐Metal‐Free</scp> Direct <scp>3‐Acetalation</scp> of Quinoxaline‐2( <scp> 1 <i>H</i> </scp> )‐ones
  作者：Chunhua Ma、Hui Meng、Jing Li、Xianguang Yang、Yuqin Jiang、Bing Yu

  DOI：10.1002/cjoc.202200386

  日期：2022.11.15

  Comprehensive SummaryA general transition‐metal‐free visible‐light‐promoted 3‐acetalation reaction of quinoxaline‐2(1H)‐ones was developed under mild conditions. By employing 1,2,3,5‐tetrakis(carbazol‐9‐yl)‐4,6‐dicyanobenzene (4CzIPN) as an inexpensive photocatalyst, and glyoxylic acid acetal as a radical source, various acetalated quinoxaline‐2(1H)‐ones were constructed in moderate to good yields. Moreover, the versatility of this protocol is highlighted by the successful application in the late‐stage modification of drug molecules and the various functionality transformations. The excellent antitumor activity of the acetalated product demonstrated that this streamlined and sustainable approach could have emerged as a powerful strategy for structural modification in medicinal chemistry.